158 related articles for article (PubMed ID: 12399198)
1. Optimization of DNA vaccination against cutaneous leishmaniasis.
Méndez S; Belkaid Y; Seder RA; Sacks D
Vaccine; 2002 Nov; 20(31-32):3702-8. PubMed ID: 12399198
[TBL] [Abstract][Full Text] [Related]
2. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
Méndez S; Gurunathan S; Kamhawi S; Belkaid Y; Moga MA; Skeiky YA; Campos-Neto A; Reed S; Seder RA; Sacks D
J Immunol; 2001 Apr; 166(8):5122-8. PubMed ID: 11290794
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.
Campos-Neto A; Webb JR; Greeson K; Coler RN; Skeiky YA; Reed SG
Infect Immun; 2002 Jun; 70(6):2828-36. PubMed ID: 12010969
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Iborra S; Soto M; Carrión J; Alonso C; Requena JM
Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
[TBL] [Abstract][Full Text] [Related]
5. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells.
Gurunathan S; Stobie L; Prussin C; Sacks DL; Glaichenhaus N; Iwasaki A; Fowell DJ; Locksley RM; Chang JT; Wu CY; Seder RA
J Immunol; 2000 Jul; 165(2):915-24. PubMed ID: 10878366
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
[TBL] [Abstract][Full Text] [Related]
7. High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection.
Sánchez-Sampedro L; Gómez CE; Mejías-Pérez E; Sorzano CO; Esteban M
PLoS One; 2012; 7(6):e38859. PubMed ID: 22715418
[TBL] [Abstract][Full Text] [Related]
8. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major.
Belkaid Y; Von Stebut E; Mendez S; Lira R; Caler E; Bertholet S; Udey MC; Sacks D
J Immunol; 2002 Apr; 168(8):3992-4000. PubMed ID: 11937556
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection.
Rhee EG; Mendez S; Shah JA; Wu CY; Kirman JR; Turon TN; Davey DF; Davis H; Klinman DM; Coler RN; Sacks DL; Seder RA
J Exp Med; 2002 Jun; 195(12):1565-73. PubMed ID: 12070284
[TBL] [Abstract][Full Text] [Related]
10. Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania.
Dondji B; Deak E; Goldsmith-Pestana K; Perez-Jimenez E; Esteban M; Miyake S; Yamamura T; McMahon-Pratt D
Eur J Immunol; 2008 Mar; 38(3):706-19. PubMed ID: 18286565
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
12. Intradermal Synthetic DNA Vaccination Generates
Louis L; Clark M; Wise MC; Glennie N; Wong A; Broderick K; Uzonna J; Weiner DB; Scott P
Infect Immun; 2019 Aug; 87(8):. PubMed ID: 31182618
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of protection induced by in vitro maturated BMDCs presenting CD8
Shermeh AS; Zahedifard F; Habibzadeh S; Taheri T; Rafati S; Seyed N
Exp Parasitol; 2021 Apr; 223():108082. PubMed ID: 33581108
[TBL] [Abstract][Full Text] [Related]
14. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis.
Pérez-Jiménez E; Kochan G; Gherardi MM; Esteban M
Microbes Infect; 2006 Mar; 8(3):810-22. PubMed ID: 16504562
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with TAT-antigen fusion protein induces protective, CD8(+) T cell-mediated immunity against Leishmania major.
Kronenberg K; Brosch S; Butsch F; Tada Y; Shibagaki N; Udey MC; von Stebut E
J Invest Dermatol; 2010 Nov; 130(11):2602-10. PubMed ID: 20574442
[TBL] [Abstract][Full Text] [Related]
16. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.
Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC
Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428
[TBL] [Abstract][Full Text] [Related]
17. Comparative Assessment of Induced Immune Responses Following Intramuscular Immunization with Fusion and Cocktail of LeIF, LACK and TSA Genes Against Cutaneous Leishmaniasis in BALB/c Mice.
Maspi N; Ghaffarifar F; Sharifi Z; Dalimi A; Dayer MS
Arch Immunol Ther Exp (Warsz); 2018 Feb; 66(1):55-64. PubMed ID: 28779346
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the murine immune response to Leishmania meta 1 antigen delivered as recombinant protein or DNA vaccine.
Serezani CH; Franco AR; Wajc M; Umada Yokoyama-Yasunaka JK; Wunderlich G; Borges MM; Uliana SR
Vaccine; 2002 Nov; 20(31-32):3755-63. PubMed ID: 12399206
[TBL] [Abstract][Full Text] [Related]
19. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis.
Sjölander A; Baldwin TM; Curtis JM; Handman E
J Immunol; 1998 Apr; 160(8):3949-57. PubMed ID: 9558102
[TBL] [Abstract][Full Text] [Related]
20. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice.
Rafati S; Ghaemimanesh F; Zahedifard F
Vaccine; 2006 Apr; 24(16):3290-7. PubMed ID: 16481076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
